# Naringin Dihydrochalcone

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/naringin-dihydrochalcone
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-28
**Evidence Score:** 2 / 10
**Category:** Compound
**Also Known As:** NDC, Naringin DC, Hydrogenated naringin, Naringin dihydrochalcoside, Synthetic naringin derivative, 4',5,7-Trihydroxydihydrochalcone 7-neohesperidoside

## Overview

Naringin dihydrochalcone is a synthetic flavonoid derivative created by hydrogenating naringin from citrus fruits. It functions primarily through cytochrome P450 enzyme inhibition and suppression of the [inflammatory](/ingredients/condition/inflammation) NF-κB signaling pathway.

## Health Benefits

• [Antioxidant activity](/ingredients/condition/antioxidant) - exhibits antioxidant properties though specific clinical evidence not available
• CYP enzyme inhibition - shown to inhibit cytochrome P450 enzymes in laboratory studies
• NF-κB signaling suppression - associated with suppression of inflammatory NF-κB pathway in preclinical research
• Potential [anti-inflammatory](/ingredients/condition/inflammation) effects - targets MAPK/ERK and PI3K/Akt/mTOR pathways in laboratory studies
• Membrane transporter modulation - interacts with transporters like BCRP and CFTR channels in preliminary research

## Mechanism of Action

Naringin dihydrochalcone inhibits cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9, affecting drug [metabolism](/ingredients/condition/weight-management) pathways. The compound suppresses nuclear factor-kappa B (NF-κB) signaling, reducing [inflammatory](/ingredients/condition/inflammation) cytokine production. Its dihydrochalcone structure enhances stability and bioavailability compared to the parent naringin compound.

## Clinical Summary

Current evidence for naringin dihydrochalcone comes primarily from laboratory and preclinical studies rather than human clinical trials. In vitro studies have demonstrated significant cytochrome P450 enzyme inhibition with IC50 values in the micromolar range. Animal studies show [anti-inflammatory](/ingredients/condition/inflammation) effects through NF-κB pathway suppression, but specific dosages and clinical translation remain unclear. Human clinical data is lacking, making it difficult to establish therapeutic efficacy or optimal dosing protocols.

## Nutritional Profile

Naringin dihydrochalcone (naringin DC) is a semi-synthetic flavonoid derivative (C₂₇H₃₄O₁₅, MW ~582.54 g/mol) produced by catalytic hydrogenation of naringin, a naturally occurring flavanone glycoside found in citrus fruits. It is not a nutritional food source but rather a single bioactive compound used primarily as a high-intensity sweetener (approximately 300–1,800 times sweeter than sucrose, depending on concentration and matrix). Key biochemical characteristics: • Classification: Dihydrochalcone glycoside (flavonoid subclass). • Core bioactive structure: Dihydrochalcone aglycone backbone with a neohesperidose (rhamnose-glucose) sugar moiety attached at the 2'-position. • Caloric contribution: Essentially negligible at typical usage levels (employed at mg quantities due to extreme sweetness potency). • No significant macronutrient content (no protein, fat, or dietary fiber). • No meaningful vitamin or mineral content. • Bioactive properties stem from the polyphenolic hydroxyl groups on the aromatic rings, which confer [antioxidant](/ingredients/condition/antioxidant) capacity (ORAC and DPPH radical scavenging activity documented in vitro). • Bioavailability notes: Oral bioavailability is limited by extensive first-pass [metabolism](/ingredients/condition/weight-management); the neohesperidose sugar is cleaved by intestinal microflora (primarily by α-rhamnosidase and β-glucosidase), yielding the aglycone phloretin and free sugars. Phloretin, the primary metabolite, undergoes further glucuronidation and sulfation in the liver. Absorption is primarily in the colon following microbial deglycosylation, resulting in delayed Tmax. Estimated oral bioavailability of intact compound is low (<5–10%), though colonic metabolites (phloretin glucuronides) circulate systemically. • Solubility: Moderately soluble in water (~1 g/L at 25°C); solubility improves in alkaline conditions and ethanol-water mixtures. • Approved as a food additive/sweetener (E959) in the European Union and several other jurisdictions; ADI set at 0–5 mg/kg body weight/day by JECFA. • Contains no known allergenic proteins, gluten, or common food allergens. • Residual naringin content may be present in commercial preparations depending on hydrogenation completeness (typically <2%).

## Dosage & Preparation

No clinically studied dosage ranges have been established for naringin dihydrochalcone. Commercial products are available as powder with >95% purity. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Naringin dihydrochalcone may interact with medications metabolized by cytochrome P450 enzymes, particularly CYP3A4 and CYP2C9 substrates. This could potentially alter blood levels of drugs including certain statins, blood thinners, and immunosuppressants. Common side effects and contraindications have not been well-established due to limited human studies. Pregnant and breastfeeding women should avoid supplementation due to insufficient safety data.

## Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses were identified in the available research. Current evidence is limited to chemical characterization and preliminary laboratory studies on cellular pathways.

## Historical & Cultural Context

No historical or traditional medicine uses are documented for naringin dihydrochalcone. As a synthetic compound derived from citrus flavonoids, it lacks established use in traditional systems like Ayurveda or Traditional Chinese Medicine.

## Synergistic Combinations

Vitamin C, Quercetin, Hesperidin, Bioflavonoids, Citrus Extract

## Frequently Asked Questions

### What is the difference between naringin and naringin dihydrochalcone?

Naringin dihydrochalcone is a synthetic derivative created by hydrogenating natural naringin from citrus fruits. This chemical modification enhances its stability, bioavailability, and potency compared to the parent naringin compound.

### Does naringin dihydrochalcone interact with blood pressure medications?

Naringin dihydrochalcone may interact with blood pressure medications metabolized by CYP3A4 enzymes, including some calcium channel blockers. This interaction could potentially alter drug blood levels and effectiveness, requiring medical supervision.

### What foods naturally contain naringin dihydrochalcone?

Naringin dihydrochalcone does not occur naturally in foods as it is a synthetic compound. The parent compound naringin is found in citrus fruits, particularly grapefruit peel and bitter oranges.

### How much naringin dihydrochalcone should I take daily?

No established dosage recommendations exist for naringin dihydrochalcone due to lack of human clinical trials. Most research has been conducted in laboratory settings using varying concentrations measured in micromolar ranges.

### Can naringin dihydrochalcone help with inflammation?

Preclinical studies suggest naringin dihydrochalcone may reduce inflammation through NF-κB pathway suppression. However, human clinical evidence is lacking, making it unclear whether these anti-inflammatory effects translate to real-world benefits.

### Does naringin dihydrochalcone inhibit cytochrome P450 enzymes like grapefruit does?

Yes, laboratory studies demonstrate that naringin dihydrochalcone inhibits cytochrome P450 enzymes, similar to compounds found in grapefruit. This means it may potentially affect the metabolism of medications that rely on CYP450 pathways, though clinical evidence on the magnitude of this effect in humans is limited. If you take medications metabolized by CYP3A4 or other CYP enzymes, consult your healthcare provider before supplementing with naringin dihydrochalcone.

### Is naringin dihydrochalcone safe during pregnancy and breastfeeding?

There is insufficient clinical evidence to establish the safety of naringin dihydrochalcone supplementation during pregnancy and breastfeeding. While preclinical research suggests potential effects on inflammatory pathways (MAPK/ERK and PI3K/Akt/mTOR signaling), these findings have not been validated in pregnant or nursing populations. Pregnant and breastfeeding women should consult their healthcare provider before using this supplement.

### What does the current clinical evidence show about naringin dihydrochalcone's effectiveness?

Most evidence for naringin dihydrochalcone comes from laboratory and preclinical studies demonstrating antioxidant properties and suppression of inflammatory NF-κB signaling pathways. However, high-quality clinical trials in humans are limited, making it difficult to confirm the strength and real-world significance of these effects. More rigorous human research is needed to establish definitive health benefits and optimal therapeutic dosing.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*